VALLEY FORGE, Pa.--(BUSINESS WIRE)--Jul. 5, 2018--
AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans
to release its results for the Third Quarter Fiscal 2018 on Thursday,
August 2, 2018 prior to the opening of trading on the New York Stock
Exchange. The Company will host a conference call to discuss the results
at 8:30 a.m. ET on August 2, 2018.
Participating in the conference call will be:
Steven H. Collis, Chairman, President & Chief Executive Officer
Tim
G. Guttman, Executive Vice President & Chief Financial Officer
The dial-in number for the live call will be (612) 326-1011. No access
code is required. The live call will also be webcast via the Company’s
website at investor.amerisourcebergen.com.
Users are encouraged to log on to the webcast approximately 10 minutes
in advance of the scheduled start time of the call.
Replays of the call will be made available via telephone and webcast. A
replay of the webcast will be posted on investor.amerisourcebergen.com
approximately two hours after the completion of the call and will remain
available for 30 days. The telephone replay will also be available
approximately two hours after the completion of the call and will remain
available for one month. To access the telephone replay from within the
U.S., dial (800) 475-6701. From outside the U.S., dial (320) 365-3844.
The access code for the replay is 451454.
About AmerisourceBergen
AmerisourceBergen provides pharmaceutical products, value-driving
services and business solutions that improve access to care. Tens of
thousands of healthcare providers, veterinary practices and livestock
producers trust us as their partner in the pharmaceutical supply chain.
Global manufacturers depend on us for services that drive commercial
success for their products. Through our daily work—and powered by our
21,000 associates—we are united in our responsibility to create
healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500,
with more than $150 billion in annual revenue. The company is
headquartered in Valley Forge, Pa. and has a presence in 50+ countries.
Learn more at investor.amerisourcebergen.com.
AmerisourceBergen's Cautionary Note Regarding Forward-Looking
Statements
Certain of the statements contained in this press release are
“forward-looking statements” within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934, as amended (the “Exchange Act”). Words such as “expect,” “likely,”
“outlook,” “forecast,” “would,” “could,” “should,” “can,” “project,”
“intend,” “plan,” “continue,” “sustain,” “synergy,” “on track,”
“believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,”
“assume,” variations of such words, and similar expressions are intended
to identify such forward-looking statements. These statements are based
on management’s current expectations and are subject to uncertainty and
change in circumstances. These statements are not guarantees of future
performance and are based on assumptions that could prove incorrect or
could cause actual results to vary materially from those indicated.
Among the factors that could cause actual results to differ materially
from those projected, anticipated, or implied are the following:
unfavorable trends in brand and generic pharmaceutical pricing,
including in rate or frequency of price inflation or deflation;
competition and industry consolidation of both customers and suppliers
resulting in increasing pressure to reduce prices for the Company’s
products and services; changes in pharmaceutical market growth rates;
changes in the United States healthcare and regulatory environment,
including changes that could impact prescription drug reimbursement
under Medicare and Medicaid; increasing governmental regulations
regarding the pharmaceutical supply channel and pharmaceutical
compounding; declining reimbursement rates for pharmaceuticals; federal
and state government enforcement initiatives to detect and prevent
suspicious orders of controlled substances and the diversion of
controlled substances; increased public concern over the abuse of opioid
medications; prosecution or suit by federal, state and other
governmental entities of alleged violations of laws and regulations
regarding controlled substances, and any related disputes, including
shareholder derivative lawsuits; increased federal scrutiny and
litigation, including qui tam litigation, for alleged violations of laws
and regulations governing the marketing, sale, purchase and/or
dispensing of pharmaceutical products or services, and associated
reserves and costs, including the reserve recorded in connection with
the proceedings with the United States Attorney’s Office for the Eastern
District of New York; material adverse resolution of pending legal
proceedings; the retention of key customer or supplier relationships
under less favorable economics or the adverse resolution of any contract
or other dispute with customers or suppliers; changes to customer or
supplier payment terms; risks associated with the strategic, long-term
relationship between Walgreens Boots Alliance, Inc. and the Company,
including principally with respect to the pharmaceutical distribution
agreement and/or the global generic purchasing services arrangement;
changes in tax laws or legislative initiatives that could adversely
affect the Company’s tax positions and/or the Company’s tax liabilities
or adverse resolution of challenges to the Company’s tax positions;
regulatory action in connection with the production, labeling or
packaging of products compounded by the Company’s compounded sterile
preparations (CSP) business; suspension of production of CSPs, including
at our Memphis 503B outsourcing facility; failure to realize the
expected benefits from the Company’s reorganization and other business
process initiatives; managing foreign expansion, including
non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery
laws and economic sanctions and import laws and regulations; declining
economic conditions in the United States and abroad; financial market
volatility and disruption; substantial defaults in payment, material
reduction in purchases by or the loss, bankruptcy or insolvency of a
major customer; the loss, bankruptcy or insolvency of a major supplier;
changes to the customer or supplier mix; malfunction, failure or breach
of sophisticated information systems to operate as designed; risks
generally associated with data privacy regulation and the international
transfer of personal data; natural disasters or other unexpected events
that affect the Company’s operations; the impairment of goodwill or
other intangible assets (including with respect to foreign operations),
resulting in a charge to earnings; the acquisition of businesses that do
not perform as expected, or that are difficult to integrate or control,
including the integration of H. D. Smith and PharMEDium, or the
inability to capture all of the anticipated synergies related thereto or
to capture the anticipated synergies within the expected time period;
the effects of disruption from the transactions on the respective
businesses of the Company and H. D. Smith and the fact that the
transactions may make it more difficult to establish or maintain
relationships with employees, suppliers, customers and other business
partners; the disruption of the Company’s cash flow and ability to
return value to its stockholders in accordance with its past practices;
interest rate and foreign currency exchange rate fluctuations; and other
economic, business, competitive, legal, tax, regulatory and/or
operational factors affecting the Company’s business generally. Certain
additional factors that management believes could cause actual outcomes
and results to differ materially from those described in forward-looking
statements are set forth (i) in Item 1A (Risk Factors) in the Company’s
Annual Report on Form 10-K for the fiscal year ended September 30, 2017
and elsewhere in that report and (ii) in other reports filed by the
Company pursuant to the Securities Exchange Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180705005459/en/
Source: AmerisourceBergen Corporation
AmerisourceBergen Corporation
Bennett Murphy
Vice
President, Investor Relations
610-727-3693
bmurphy@amerisourcebergen.com